Skip to main content
OpenTrials
Completed

NCT Number: NCT06871280

Assessment of Vertigo and Dizziness in Individuals Following COVID-19

This cross-sectional study aimed to assess the prevalence of dizziness/vertigo in individuals following COVID-19 and to investigate potential risk factors associated with these symptoms. A total of 296 patients aged 20-66 years who had recovered from COVID-19 were evaluated at Istanbul Physical Medicine and Rehabilitation Training and Research Hospital between June 1, 2021, and December 31, 2021. Clinical and demographic data, including COVID-19 history, comorbidities, and symptom characteristics, were collected. Dizziness-related disability was assessed using the Dizziness Handicap Inventory (DHI), while balance performance was evaluated with the Berg Balance Scale (BBS).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

20 year–66 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Istanbul Physical Medicine Rehabilitation Training and Research Hospital

Istanbul, Turkey (Türkiye)

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals aged 20-66 years.
  • History of confirmed COVID-19 infection.
  • Ability to speak and understand Turkish.
  • Willingness to provide verbal and written informed consent.

Exclusion criteria

  • Pre-existing vertigo or balance disorders (e.g., benign paroxysmal positional vertigo, Ménière's disease, vestibular migraine, vestibular neuritis).
  • Inner ear diseases or vestibular dysfunction.
  • Neurological disorders affecting balance (e.g., multiple sclerosis, Parkinson's disease, history of stroke, epilepsy).
  • Psychiatric conditions that could cause dizziness (e.g., anxiety, panic attacks, depression).
  • History of head or neck trauma in the past six months.
  • Moderate to severe visual impairment.
  • Chronic alcohol or substance use.
  • Use of ototoxic medications.
  • Severe cardiovascular diseases (e.g., orthostatic hypotension, advanced heart failure, severe arrhythmias).
  • Pregnant or breastfeeding women.
  • Acute infection other than COVID-19 in the past three months.
  • Severe COVID-19 requiring hospitalization

Treatment and study plan

Primary outcomes

  1. Dizziness Handicap Inventory

    Time frame: 0 day

    Prevalence of dizziness/vertigo in individuals following COVID-19, assessed using the Dizziness Handicap Inventory (DHI).

    Range: 0-100 (Higher scores indicate greater dizziness-related disability).

Secondary outcomes

  1. Berg Balance Scale (BBS)

    Time frame: 0 day

    Balance status evaluated using the Berg Balance Scale (BBS). Range: 0-56 (Higher scores indicate better balance)

Sponsors and collaborators

Lead sponsor

Istanbul Physical Medicine Rehabilitation Training and Research Hospital

Other Gov

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Mar 11, 2025
Registry last updated
Mar 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.